bionlp-st-ge-2016-spacy-parsed Home  

PMC:3586680 / 15852-16273 JSONTXT 21 Projects

Annnotations TAB TSV DIC JSON TextAE

Id Subject Object Predicate Lexical cue
T9180 0-3 NN denotes p53
T9181 4-11 NNS denotes mutants
T9182 12-15 VBP denotes are
T9183 16-26 VBN denotes considered
T9184 27-29 IN denotes as
T9185 30-41 JJ denotes unfavorable
T9186 42-49 NNS denotes factors
T9187 50-53 IN denotes for
T9188 54-57 DT denotes the
T9189 58-71 NN denotes effectiveness
T9190 72-74 IN denotes in
T9191 75-87 JJ denotes radiotherapy
T9192 88-91 CC denotes and
T9193 92-95 NNP denotes TMZ
T9194 96-105 NN denotes treatment
T9195 106-108 IN denotes in
T9196 109-115 NN denotes glioma
T9197 116-121 NNS denotes cells
T9198 122-123 -LRB- denotes (
T9199 123-130 NNP denotes Gjerset
T9200 131-133 FW denotes et
T9201 134-137 FW denotes al.
T9202 137-138 , denotes ,
T9203 139-143 CD denotes 1995
T9204 143-144 : denotes ;
T9205 145-151 NNP denotes Hirose
T9206 152-154 FW denotes et
T9207 155-158 FW denotes al.
T9208 158-159 , denotes ,
T9209 160-164 CD denotes 2001
T9210 164-165 : denotes ;
T9211 166-175 NNP denotes Squatrito
T9212 176-178 FW denotes et
T9213 179-182 FW denotes al.
T9214 182-183 , denotes ,
T9215 184-188 CD denotes 2010
T9216 188-189 : denotes ;
T9217 190-196 NNP denotes Blough
T9218 197-199 FW denotes et
T9219 200-203 FW denotes al.
T9220 203-204 , denotes ,
T9221 205-209 CD denotes 2011
T9222 209-210 -RRB- denotes )
T9223 210-211 . denotes .
T9224 212-216 NN denotes Loss
T9225 217-219 IN denotes of
T9226 220-230 JJ denotes functional
T9227 231-234 NN denotes p53
T9228 235-242 VBZ denotes confers
T9229 243-254 NN denotes sensitivity
T9230 255-257 TO denotes to
T9231 258-261 NNP denotes TMZ
T9232 262-264 IN denotes in
T9233 265-271 NN denotes glioma
T9234 272-277 NNS denotes cells
T9235 277-278 , denotes ,
T9236 279-286 IN denotes whereas
T9237 287-291 JJ denotes wild
T9238 292-296 NN denotes type
T9239 297-300 NN denotes p53
T9240 301-310 VBZ denotes increases
T9241 311-314 DT denotes the
T9242 315-318 NNP denotes TMZ
T9243 319-329 NN denotes resistance
T9244 330-331 -LRB- denotes (
T9245 331-337 JJ denotes Blough
T9246 338-340 FW denotes et
T9247 341-344 FW denotes al.
T9248 344-345 , denotes ,
T9249 346-350 CD denotes 2011
T9250 350-351 -RRB- denotes )
T9251 351-352 . denotes .
T9252 353-356 NN denotes p53
T9253 357-364 NNS denotes mutants
T9254 365-371 VB denotes reduce
T9255 372-375 NNP denotes TMZ
T9256 376-387 NN denotes sensitivity
T9257 388-390 IN denotes in
T9258 391-398 NNS denotes gliomas
T9259 399-400 -LRB- denotes (
T9260 400-406 JJ denotes Blough
T9261 407-409 FW denotes et
T9262 410-413 FW denotes al.
T9263 413-414 , denotes ,
T9264 415-419 CD denotes 2011
T9265 419-420 -RRB- denotes )
T9266 420-421 . denotes .
R6238 T9180 T9181 compound p53,mutants
R6239 T9181 T9183 nsubjpass mutants,considered
R6240 T9182 T9183 auxpass are,considered
R6241 T9183 T9219 ccomp considered,al.
R6242 T9184 T9183 prep as,considered
R6243 T9185 T9186 amod unfavorable,factors
R6244 T9186 T9184 pobj factors,as
R6245 T9187 T9186 prep for,factors
R6246 T9188 T9189 det the,effectiveness
R6247 T9189 T9187 pobj effectiveness,for
R6248 T9190 T9189 prep in,effectiveness
R6249 T9191 T9194 amod radiotherapy,treatment
R6250 T9192 T9191 cc and,radiotherapy
R6251 T9193 T9194 compound TMZ,treatment
R6252 T9194 T9190 pobj treatment,in
R6253 T9195 T9189 prep in,effectiveness
R6254 T9196 T9197 compound glioma,cells
R6255 T9197 T9195 pobj cells,in
R6256 T9198 T9201 punct (,al.
R6257 T9199 T9201 nmod Gjerset,al.
R6258 T9200 T9201 nmod et,al.
R6259 T9201 T9186 appos al.,factors
R6260 T9202 T9201 punct ",",al.
R6261 T9203 T9201 npadvmod 1995,al.
R6262 T9204 T9219 punct ;,al.
R6263 T9205 T9207 compound Hirose,al.
R6264 T9206 T9207 nmod et,al.
R6265 T9207 T9219 ccomp al.,al.
R6266 T9208 T9207 punct ",",al.
R6267 T9209 T9207 npadvmod 2001,al.
R6268 T9210 T9219 punct ;,al.
R6269 T9211 T9213 compound Squatrito,al.
R6270 T9212 T9213 compound et,al.
R6271 T9213 T9219 ccomp al.,al.
R6272 T9214 T9213 punct ",",al.
R6273 T9215 T9213 npadvmod 2010,al.
R6274 T9216 T9219 punct ;,al.
R6275 T9217 T9219 compound Blough,al.
R6276 T9218 T9219 compound et,al.
R6277 T9219 T9219 ROOT al.,al.
R6278 T9220 T9219 punct ",",al.
R6279 T9221 T9219 npadvmod 2011,al.
R6280 T9222 T9219 punct ),al.
R6281 T9223 T9219 punct .,al.
R6282 T9224 T9228 nsubj Loss,confers
R6283 T9225 T9224 prep of,Loss
R6284 T9226 T9227 amod functional,p53
R6285 T9227 T9225 pobj p53,of
R6286 T9228 T9228 ROOT confers,confers
R6287 T9229 T9228 dobj sensitivity,confers
R6288 T9230 T9229 prep to,sensitivity
R6289 T9231 T9230 pobj TMZ,to
R6290 T9232 T9228 prep in,confers
R6291 T9233 T9234 amod glioma,cells
R6292 T9234 T9232 pobj cells,in
R6293 T9235 T9228 punct ",",confers
R6294 T9236 T9240 mark whereas,increases
R6295 T9237 T9239 amod wild,p53
R6296 T9238 T9239 compound type,p53
R6297 T9239 T9240 nsubj p53,increases
R6298 T9240 T9228 advcl increases,confers
R6299 T9241 T9243 det the,resistance
R6300 T9242 T9243 compound TMZ,resistance
R6301 T9243 T9240 dobj resistance,increases
R6302 T9244 T9240 punct (,increases
R6303 T9245 T9247 amod Blough,al.
R6304 T9246 T9247 nmod et,al.
R6305 T9247 T9240 npadvmod al.,increases
R6306 T9248 T9247 punct ",",al.
R6307 T9249 T9247 npadvmod 2011,al.
R6308 T9250 T9240 punct ),increases
R6309 T9251 T9228 punct .,confers
R6310 T9252 T9253 compound p53,mutants
R6311 T9253 T9254 nsubj mutants,reduce
R6312 T9254 T9254 ROOT reduce,reduce
R6313 T9255 T9256 compound TMZ,sensitivity
R6314 T9256 T9254 dobj sensitivity,reduce
R6315 T9257 T9256 prep in,sensitivity
R6316 T9258 T9257 pobj gliomas,in
R6317 T9259 T9262 punct (,al.
R6318 T9260 T9262 amod Blough,al.
R6319 T9261 T9262 nmod et,al.
R6320 T9262 T9254 advmod al.,reduce
R6321 T9263 T9262 punct ",",al.
R6322 T9264 T9262 npadvmod 2011,al.
R6323 T9265 T9262 punct ),al.
R6324 T9266 T9254 punct .,reduce